論文

査読有り
2017年7月1日

Safety of one-week, first-line, standard triple therapy for Helicobacter pylori eradication in a Japanese population

Current Drug Safety
  • Kazutoshi Hori
  • ,
  • Tetsuya Takagawa
  • ,
  • Nobuyuki Hida
  • ,
  • Shiro Nakamura

12
2
開始ページ
103
終了ページ
109
記述言語
英語
掲載種別
DOI
10.2174/1574886312666170310100209
出版者・発行元
Bentham Science Publishers B.V.

Background: Standard triple therapy with the proton pump inhibitors, clarithromycin and amoxicillin for Helicobacter pylori infection is considered to be safe
however, the development of significant adverse events (AEs), such as skin rashes, has been reported. Objective: To reconfirm the safety of this treatment. Methods: This was a retrospective cohort study. After the exclusion of patients allergic to penicillin, 322 consecutive patients, consisting of 305 outpatients and 17 inpatients, had received the first-line eradication treatment with lansoprazole (30 mg), clarithromycin (200 mg), and amoxicillin (750 mg) twice daily for 7 days. Their medical charts were reviewed, and data were collected. Results: Three patients discontinued the treatment because of the development of a skin rash, mild diarrhea, and heat sensation, respectively. The main AE observed was mild diarrhea in 50 patients. One patient had frequent diarrhea, but it was readily resolved by a probiotic treatment. On the second or third day after the conclusion of the treatment, a skin rash also occurred in six patients (2%). Two of these patients and one patient who discontinued the treatment were administered steroids as outpatients. They recovered within 1 month. Conclusion: Most AEs that developed were mild, except for some cases of a rash. Rashes developed in spite of the exclusion of penicillin-allergic patients and mainly after the completion of the one-week treatment. As a consequence of little previous exposure to penicillin in the Japanese population, the development of delayed rashes after this exclusion may represent first sensitization to penicillin.

リンク情報
DOI
https://doi.org/10.2174/1574886312666170310100209
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/28294071

エクスポート
BibTeX RIS